• Biotech Snap
  • Posts
  • Spain raises $200M to create a biotech bridge with Boston & Beeline launches with $300M and a ready-made autoimmune pipeline

Spain raises $200M to create a biotech bridge with Boston & Beeline launches with $300M and a ready-made autoimmune pipeline

AuthorAuthor

Joachim Eeckhout & Eduardo Longoria
April 16, 2026

Good morning. Today’s newsletter, prepared by Joachim E. and Eduardo L., is 1,000 words, a 7-min. read. Enjoy today’s read.

Here’s the best way to support our daily work: Forward Biotech Snap to a friend!

Was this email forwarded to you? Sign up here.

SNAPSHOT

Spain targets $200M VC fund to plug its biotechs into Boston’s ecosystem

The Spanish Flag

Spain plans to raise a $200 million venture capital fund, backed by ~$57 million in government support, to connect Spanish biotech firms with Boston’s life sciences hub.

Why it matters: The initiative aims to give Spanish startups access to top-tier U.S. infrastructure, talent, and investors, while boosting innovation, job creation, and cross-border growth.

Backstory: Boston remains a global biotech leader but is facing headwinds, including layoffs (~4,600 jobs cut in 2025) and rising lab vacancies (28%). Meanwhile, Spain’s economy is robust, growing 2.8% last year and increasing investments in domestic biotech.

Big picture: Governments are increasingly using venture capital as a strategic tool to globalize their innovation ecosystems, linking local companies to established hubs like Boston to accelerate scaling and competitiveness. To this point, Spain has recently backed Oncomatryx’s $67M Series B, signaling stronger biotech ambitions.

What’s next: Spain will raise capital from private investors and begin deploying funds to support Spanish biotech expansion into Boston. Officials hint that there is potential to extend the model beyond biotech into other high-growth industries.

SNAP AGAIN

Beeline Medicines launches with $300M and a ready-made autoimmune pipeline from BMS

A bee tucking into some pollen

Beeline Medicines emerged from stealth with $300 million in Series A funding, five autoimmune programs licensed from Bristol Myers Squibb, and a leadership team behind SpringWorks Therapeutics’ prior success.

Why it matters: The biotech enters the crowded immunology space with significant capital, validated assets, and experienced leadership, positioning it to accelerate new treatments for lupus and related diseases affecting millions.

Backstory: Beeline is led by Saqib Islam and Badreddin Edris, former SpringWorks executives who guided the company to two FDA approvals and a $3.9B acquisition by Merck KGaA in 2025. Private investment firm Bain Capital, also a backer of SpringWorks, quickly redeployed the team into this new venture using assets spun out from BMS. The company also draws a large amount of talent from BMS with ~40 employees, heavily focused on R&D.

Big picture: Big pharma is increasingly offloading early and mid-stage assets to nimble biotech startups backed by major investors, allowing faster development while spreading risk. Beeline reflects this model, combining pharma-originated science with startup agility.

Zoom in: The lead program is afimetoran, a once-daily oral small molecule that inhibits TLR7 and TLR8, two immune targets tied to lupus biology. It has already completed phase 1b testing in cutaneous lupus erythematosus, and an ongoing phase 2 trial is expected to finish by year-end. Beyond afimetoran, Beeline’s pipeline includes an IL-2-CD25 fusion protein in phase 1b for atopic dermatitis and lupus, a phase 2 oral TYK2 inhibitor for plaque psoriasis and two preclinical biologics targeting IL-10 and IL-18.

What’s next: Beeline expects to start several new trials in the next 12 to 18 months, including moving its two preclinical assets into the clinic.

SNIPPETS

What’s happening in biotech today?

🎉 RAS rally: Revolution Medicines has raised $2 billion through a combination of stock and convertible debt, marking the biotech industry’s largest public financing since the COVID-19 pandemic and doubling its initial target following strong Phase 3 pancreatic cancer results. The raise comes amid a resurgence in biotech markets, with the XBI index reaching its highest level since 2021 and climbing over 29% in six months, alongside increased public offerings and deal activity. Investor enthusiasm is driven by daraxonrasib, a “pan-RAS” inhibitor that reduced death risk by 60% in trials, boosting the company’s valuation to over $29 billion.

🚀 Covalent climb: Terremoto Biosciences has raised $108 million in a series C round to advance its covalent drug development platform, with funds primarily supporting phase 1 trials of AKT1-selective inhibitors. Its lead candidate, TER-2013, is already in clinical testing for solid tumors with specific mutations, while a second candidate, TER-4480, is expected to enter trials for hereditary hemorrhagic telangiectasia later this year. The company focuses on targeting lysine, a widely present amino acid, to expand druggable proteins beyond traditional cysteine-based approaches.

🎯 Cancer targeting: Adcendo, a Copenhagen-based biotech, has raised an oversubscribed $75 million Series C round led by Jeito Capital to advance its antibody-drug conjugate (ADC) pipeline for hard-to-treat cancers. The funding will support early-phase clinical trials of two lead candidates, ADCE-T02 targeting Tissue Factor and ADCE-D01 targeting uPARAP, both already in Phase 1/2 studies, as well as preclinical development of a third undisclosed ADC expected to enter trials soon.

👀 Pill scrutiny: The FDA has requested additional safety data from Eli Lilly regarding potential liver injury linked to its newly approved weight-loss pill, Foundayo. Although Lilly stated no liver damage was observed in late-stage trials, the FDA is requiring multiple post-marketing studies. Foundayo recently entered the market amid competition with Novo Nordisk’s oral Wegovy. Analysts view the FDA’s requirements as precautionary and unlikely to affect the drug’s competitive position, as both treatments have shown significant weight-loss benefits in clinical trials.

TOUR OPERATOR

Upcoming events

What did you think of today's newsletter?

Your feedback helps us create the best newsletter possible.

Login or Subscribe to participate in polls.

Share the Snap!

Know someone who’d enjoy this? Hit forward and pass it along.